In vitro and in vivo effects of BT 563, an anti-interleukin-2 receptor monoclonal antibody.
BT 563, a murine anti-IL-2R MoAb, was found to be more potent than anti-Tac in inhibiting proliferation in the mixed lymphocyte reaction. Results obtained with 33B3.1 in these experiments were similar to those with BT 563. The anti-IL-2R MoAb 2A3 was shown to be a suitable agent for monitoring the effect of BT 563 on peripheral blood. IL-2R-positive cells were not detected in peripheral blood samples from 1 h after the first dose until 8 days after the last dose. Plasma trough levels were measured in patients receiving 5 or 10 mg daily. The administration of BT 563 to allograft recipients did not lead to clinically significant side effects.
Department of Internal Medicine, University Hospital Rotterdam, The Netherlands.
T
T
Van Gelder
C R
CR
Daane
L M
LM
Vaessen
C J
CJ
Hesse
B
B
Mochtar
A H
AH
Balk
W
W
Weimar
D000911:Antibodies, Monoclonal / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use*; D002478:Cells, Cultured; D004359:Drug Therapy, Combination; D006084:Graft Rejection / Q000517:prevention & control; D016027:Heart Transplantation / Q000276:immunology*; D006801:Humans; D016030:Kidney Transplantation / Q000276:immunology*; D018655:Lymphocyte Count; D007959:Lymphocyte Culture Test, Mixed; D008214:Lymphocytes / Q000187:drug effects / Q000276:immunology*; D015375:Receptors, Interleukin-2 / Q000097:blood / Q000276:immunology; D013997:Time Factors
D000911:Antibodies, Monoclonal; D015375:Receptors, Interleukin-2; C079843:inolimomab